[1] ADAY A W, MATSUSHITA K. Epidemiology of peripheral artery disease and polyvascular disease[J].Circ Res,2021,128(12):1818-1832. [2] ABOYANS V, RICCO J B, BARTELINK M E L, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries[J].Eur Heart J,2018, 39(9): 763-816. [3] GERHARD-HERMAN M D, GORNIK H L, BARRETT C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [J].Circulation,2017,135(12): e726-e779. [4] 中华医学会外科学分会血管外科学组.下肢动脉硬化闭塞症诊治指南 [J].中华普通外科学文献(电子版), 2016, 10(1):1-18. [5] FOX K A A, EIKELBOOM J W, ANAND S S, et al. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: What does COMPASS add? [J].Eur Heart J,2019, 40(18):1466-1471. [6] CAPRIE STEERING COMMITTEE. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)[J].Lancet,1996, 348(9038):1329-1339. [7] ANAND S S, BOSCH J, EIKELBOOM J W, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial [J].Lancet,2018, 391(10117):219-229. [8] BONACA M P, BAUERSACHS R M, ANAND S S, et al. Rivaroxaban in peripheral artery disease after revascularization[J].N Engl J Med,2020, 382(21):1994-2004. [9] TRAN B. Assessment and management of peripheral arterial disease: what every cardiologist should know [J].Heart,2021,107(22):1835-1843. [10] OHMAN E M, ROE M T, STEG P G, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial[J].Lancet,2017, 389(10081):1799-1808. [11] MOLL F, BAUMGARTNER I, JAFF M, et al. Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial[J].J Endovasc Ther,2018, 25(2): 158-168. [12] JETTY P, KUBELIK D, NAGPAL S, et al. PC078. Rivaroxaban plus Aspirin Versus Standard Dual Antiplatelet Therapy After Angioplasty for Lower Extremity Peripheral Artery Disease in Patients With Critical Limb Ischemia and Claudication (RIVAL-PAD)[J].J Vasc Surg,2019,69(6):e227-e228.
2024, Vol. 41 
